Radiation therapy and androgen suppression as treatment for clinically localized prostate cancer: The new standard?

JAMA

Volumn 292, Issue 7, 2004, Pages 864-866

  DeWeese, Theodore L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; GONADORELIN AGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADVANCED CANCER; ANDROGEN THERAPY; BIOCHEMISTRY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; COMBINATION CHEMOTHERAPY; EDITORIAL; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RECURRENCE RISK; SCORING SYSTEM; MALE; MULTIMODALITY CANCER THERAPY; NOTE; PROSTATE TUMOR;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 4043059938     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.7.864     Document Type: Editorial

References (26)

1. Jemel A, Tiwari RC, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2004;54:8-29.
2. Kupelian P, Katcher J, Levin H, Klein E. Stage T1-2 prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:1043-1052.
3. Kattan M, Eastham J, Stapleton A, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90;766-771.
4. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95:281-286.
5. Partin A, Mangold L, Lamm D, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 2001;58:843-848.
6. Roach M, Lu J, Pilepich M, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000;47:609-615.
7. Partin A, Piantadosi S, Sanda M, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 1995;45:831-838.
8. Pisansky T, Kahn M, Bostwick D. An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer. 1997;79:2154-2161.
9. Kattan M, Zelefsky M, Kupelian P, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352-3359.
10. D'Amico A, Whittington R, Malkowicz S, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
11. Sebo T, Bock B, Cheville J, et al. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol. 2000;163:174-178.
12. Huggins C, Stevens R, Hodges C. Studies on prostate cancer: the effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209-222.
13. Lawton C, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49:937-946.
14. Pilepich M, Winter K, John M, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243-1252.
15. Hanks G, Pajak T, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. J Clin Oncol. 2003;21:3972-3978.
16. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression. J Clin Oncol. 2003;21:1904-1911.
17. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study). Lancet. 2002;360:103-106.
18. Complete Library of NCCN Clinical Practice Guidelines in Oncology [CD-ROM]. Jenkintbwn, Pa: National Comprehensive Cancer Network; June 2004.
19. D'Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292:821-827.
20. Pound C, Partin A, Epstein J, Walsh P. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Urol Clin North Am. 1997;24:395-406.
21. D'Amico A, Cote K, Loffredo M, et al. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol. 2003;169:1320-1324.
22. Creene K, Meng M, Elkin E, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort. J Urol. 2004;171:2255-2259.
23. D'Amico A, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000;284:1280-1283.
24. Zelefsky M, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876-881.
25. Pollack A, Zagars G, Starkschall G, et al. Prostate cancer radiation dose response. Int J Radiat Oncol Biol Phys. 2002;53:1097-1105.
26. Leibel S, Fuks Z, Zelefsky M, et al. Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer. Semin Oncol. 2003;30:596-615.